MACROGENICS Granted U.S. Patent #11697684: Tri-specific binding molecules that specifically bind to multiple cancer antigens
Portfolio Pulse from Charles Gross
MACROGENICS, INC. has been granted U.S. Patent #11697684 for tri-specific binding molecules that specifically bind to multiple cancer antigens. The patent was filed on 2/28/2020 and granted on 7/11/2023.
July 11, 2023 | 1:52 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The granting of the patent to MACROGENICS, INC. could potentially increase the company's value and attract more investors.
The granting of a patent is a positive development for a biotech company like MACROGENICS, INC. It provides the company with exclusive rights to the patented technology, which could potentially lead to new products, partnerships, or licensing deals. This could increase the company's value and make it more attractive to investors, potentially leading to a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100